Journal: Annals of hematology
The publication reports a secondary efficacy analysis from the phase 3 SHINE study. It evaluated ibrutinib combined with bendamustine and rituximab (BR) versus placebo plus BR as first-line treatment in patients aged ≥65 years with untreated stage II-IV mantle cell lymphoma (MCL).
After a median follow-up of 94.5 months, patients who achieved a complete response (CR) demonstrated significantly longer progression-free survival (PFS) compared to those with partial response or stable/progressive disease.
The ibrutinib plus BR group had higher odds of achieving CR, with an odds ratio of 1.48.
Overall, achieving CR correlated with prolonged long-term PFS, and ibrutinib plus BR increased the likelihood of CR in this population.